Bausch & Lomb Corp
BLCO: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$99.00 | Qcdym | Fktxkfvs |
Bausch & Lomb Earnings: Product Launches Across Segments Support Solid Top-Line Growth
Narrow-moat Bausch & Lomb reported solid second-quarter results, with top-line growth and EPS exceeding our expectations. Total sales were up 18% year over year to $1.2 billion, mainly driven by healthy demand for vision care products and contributions from drugs Xiidra and Miebo. We maintain our fair value estimate of $19 (CAD 26) per share and believe near-term product launches, led by the Infuse portfolio and Miebo, should add to the company’s intangible assets that reinforce its moat rating.